NIKKEI 225
38,749.25 -173.78 (-0.45%) HANG SENG
18,423.83 +20.79 (+0.11%) CRUDE OIL
73.68 -0.54 (-0.73%) GOLD FUTURES
2,367.00 -2.30 (-0.10%) DOW
38,571.03 -115.29 (-0.30%) Bitcoin GBP
53,985.59 +667.38 (+1.25%)
YMAB Aug 2024 10.000 call
| Previous close | 1.7000 |
| Open | 1.7000 |
| Bid | 6.4000 |
| Ask | 9.5000 |
| Strike | 10.00 |
| Expiry date | 2024-08-16 |
| Day's range | 1.7000 - 1.7000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
GlobeNewswireY-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting
NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the publication of preclinical GD2-SADA data at the 2024 American Society of Clinical Oncology (“ASCO”) Annual Meeting, taking place May 31 through June 4, 2024, in Chicago, IL. T
- GlobeNewswire
Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting
NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced new interim data from the Phase 2 Trial 201 of naxitamab in combination with granulocyte-macrophage colony-stimulating factor (“GM-CSF”) in patients with relapsed or refractory hi
Insider MonkeyY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q1 2024 Earnings Call Transcript
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q1 2024 Earnings Call Transcript May 8, 2024 Y-mAbs Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome to Y-mAbs Therapeutics Inc. Earnings Conference Call for the First Quarter of 2024. […]
